TB vaccines: progress and problems
TB vaccines: progress and problems
复制标题
DOI：
10.1016/s1471-4906(01)01865-8
复制
发表时间：
2001-03-01
影响因子：
16.8
通讯作者：
Andersen, P
中科院分区：
文献类型：
--
作者：
Andersen, P
结核病（TB）是全世界任何传染病的最大杀手，这种情况由于HIV流行病的出现和结核分枝杆菌的多药耐药菌株的出现而恶化。现有的疫苗，牛分枝杆菌卡介苗（BCG）。在最近的几次实地试验中被证明是无效的。目前正在利用尖端疫苗技术进行激烈的研究，以对抗这种古老的疾病，但是，在我们合理开发下一代疫苗之前，有必要了解BCG失败的原因。几个假设，可能会解释失败的BCG和旨在解决这些缺点的战略进行了讨论。
Tuberculosis (TB) is the biggest killer worldwide of any infectious disease, a situation worsened by the advent of the HIV epidemic and the emergence of multi-drug resistant strains of Mycobacterium tuberculosis. The existing vaccine, Mycobacterium bovis bacille Calmette-Guerin (BCG). has proven inefficient in several recent field trials. There is currently intense research using cutting-edge vaccine technology to combat this ancient disease, However, it is necessary to understand why BCG has failed before we can rationally develop the next generation of vaccines. Several hypotheses that might explain the failure of BCG and the strategies designed to address these shortcomings are discussed.